Our partner EpiCypher has developed the largest portfolio of fully defined and homogenous purified and recombinant nucleosomes on the market incorporating different histone modifications, site mutations and variants.
Nuclesomes are the physiological target of readers, writers and erasers that interact with or modify chromatin. Proteins that write, read or erase ‘histone code’ are mutated in cancer and other diseases making them popular drug targets. The incorporation of nucleosome substrates into drug discovery assays is a dramatic improvement over peptides, providing access to historically challenging targets.